# EDGAR Filing Document

**Accession Number:** 0001477845
**File Stem:** 0001104659-26-075198
**Filing Date:** 2026-6
**Character Count:** 8290
**Document Hash:** 0bd59eb4e7c7b7e442b7819f522ef0ab
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-075198.hdr.sgml**: 20260617

**ACCESSION NUMBER**: 0001104659-26-075198

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260617

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260617

**DATE AS OF CHANGE**: 20260617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Annovis Bio, Inc.
- **CENTRAL INDEX KEY:** 0001477845
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 262540421
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39202
- **FILM NUMBER:** 261099244

**BUSINESS ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE, SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 484-875-3192

**MAIL ADDRESS:**
- **STREET 1:** 101 LINDENWOOD DRIVE, SUITE 225
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** QR Pharma, Inc.
- **DATE OF NAME CHANGE:** 20091202

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 17, 2026**

**ANNOVIS BIO, INC.**

**(Exact Name of Registrant as Specified in Charter)** 

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39202** | **26-2540421** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**101 Lindenwood Drive** **, Suite 225 Malvern, PA 19355** 

**(Address of Principal Executive Offices, and Zip Code)**

**(484) 875-3192**

**Registrant's Telephone Number, Including Area Code**

**<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not Applicable&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u>**

**(Former Name or Former Address, if Changed Since Last Report)**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $0.0001 per share** | **ANVS** | **New York Stock Exchange** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

◻ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

On June 17, 2026, Annovis Bio, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") virtually. At the Annual Meeting, five proposals were submitted to the Company's stockholders and all matters voted upon were approved with the required votes. The proposals are outlined below and further described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 30, 2026.

At the Annual Meeting, a total of 21,705,113 shares of the Company's common stock, or 62.65% of the common stock outstanding as of April 28, 2026, the record date for the Annual Meeting, were represented virtually or by proxy.

The following is a brief description of the final voting results for each of the five proposals submitted at the Annual Meeting on June 17, 2026:

**1. Election of Directors**

All of the following five nominees were elected to the Company's Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.

---

| | | | |
|:---|:---|:---|:---|
| **Nominees:** | **For** | **Withold** | **Broker Non-Vote** |
| Michael Hoffman | 8,604,453 | 550,520 | 12,550,140 |
| Maria Maccecchini | 8588620 | 566,353 | 12,550,140 |
| Claudine Bruck | 8,666,606 | 488,367 | 12550140 |
| Reid McCarthy | 8,591,131 | 563842 | 12550140 |
| Mark White | 8,204,328 | 950,645 | 12550140 |

---

**2. Ratification of the Company's Independent Auditors**

The ratification of the appointment of Ernst & Young LLP was approved by stockholders by the following vote:

---

| | | |
|:---|:---|:---|
| **For** | **Against** | **Abstain** |
| 20,634,176 | 568,155 | 502,782 |

---

**3.** **Amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan**

The amendment to the Annovis Bio, Inc. 2019 Equity Incentive Plan to increase the number of shares that may be issued under the Plan from 4,000,000 to 5,500,000 and to increase the maximum number of shares that may be awarded in any one year from 400,000 to 600,000 shares, was approved by stockholders by the following vote:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Vote** |
| 8,089,891 | 899,671 | 165409 | 12550142 |

---

**4.** **ADVISORY (NON-BINDING) VOTE ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS**

The compensation of the Company's named executive officers was approved by the stockholders on an advisory (non-binding basis), by the following vote:

**Broker Non-Vote**

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Vote** |
| 8,067,931 | 901,342 | 185,701 | 12550139 |

---

**5.** **ADVISORY (NON-BINDING) VOTE ON THE PREFERRED FREQUENCY OF FUTURE ADVISORY VOTES ON COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS**

"**TWO YEARS**" as the preferred frequency on the compensation of the Company's named executive officers was approved by stockholders on an advisory (non-binding basis), by the following vote:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **1-Year** | **2-Years** | **3-Years** | **Abstain** | **Broker Non-Vote** |
| 2,526,008 | 5,390,514 | 1086528 | 151,922 | 12550141 |

---

(d) In light of this vote, and consistent with the recommendation of the Board of Directors, the Company has determined that it will include a stockholder advisory vote on executive compensation in its proxy materials every two years until the next required advisory vote on the frequency of such votes occurs, or until the Board of Directors otherwise determines a different frequency for such votes.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits** |

---

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ANNOVIS BIO, INC.** | **ANNOVIS BIO, INC.** |
| Date: June 17, 2026 |  |  |
|  | By: | /s/ Maria Maccecchini |
|  | Name: | Maria Maccecchini |
|  | Title: | Chief Executive Officer |

---